During the past decade, Tokyo Medical and Dental University Hospital conducted 76 clinical trials. In the 10-year time frame, 76 clinical trials started and 27 clinical trials were completed, i.e. on average, 35.5% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 20 clinical trials were completed. i.e. 42.6% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Tokyo Medical and Dental University Hospital" #1 sponsor was "Eli Lilly and Company" with 13 trials, followed by "Pfizer" with 8 trials sponsored, "Hoffmann-La Roche" with 7 trials sponsored, "Janssen Research & Development, LLC" with 7 trials sponsored and "Haruhiko Fukuda" with 7 trials sponsored. Other sponsors include 50 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Tokyo Medical and Dental University Hospital" #1 collaborator was "Ministry of Health, Labour and Welfare, Japan" with 6 trials as a collaborator, "Gilead Sciences" with 3 trials as a collaborator, "Japan Agency for Medical Research and Development" with 2 trials as a collaborator, "Japan Clinical Oncology Group" with 2 trials as a collaborator and "Japan Lung Cancer Society" with 2 trials as a collaborator. Other collaborators include 7 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Tokyo Medical and Dental University Hospital" are "Ulcerative Colitis" (15 trials), "Crohn's Disease" (11 trials), "Atrial Fibrillation" (4 trials), "Colitis, Ulcerative" (4 trials) and "Primary Immunodeficiency Diseases (PID)" (3 trials). Many other conditions were trialed in "Tokyo Medical and Dental University Hospital" in a lesser frequency.

Most popular intervention types in "Tokyo Medical and Dental University Hospital" are "Drug" (75 trials), "Other" (10 trials), "Biological" (8 trials), "Device" (8 trials) and "Procedure" (4 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (30 trials), "Mirikizumab" (7 trials), "Baricitinib" (4 trials), "CP-690,550" (4 trials) and "Filgotinib" (4 trials). Other intervention names were less common.

The vast majority of trials in "Tokyo Medical and Dental University Hospital" are 94 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Tokyo Medical and Dental University Hospital". undefined are not yet recruiting, 25 are recruiting, 19 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 40 completed trials in Tokyo Medical and Dental University Hospital, undefined suspended trials, and 8 terminated clinical trials to date.

Out of the total trials that were conducted in Tokyo Medical and Dental University Hospital, 2 "Phase 1" clinical trials were conducted, 23 "Phase 2" clinical trials and 62 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 5 trials that are defined as “Not Applicable".